NAVB News and Press, Navidea Biopharmaceuticals Inc. From 03/23/22

Navidea Biopharm press release (NYSE:NAVB): Q4 GAAP EPS of -$0.12. Revenue of $0.05M (-77.3% Y/Y). cash and cash equivalents of $4.2M For further details see: Navidea Biopharm GAAP EPS of -$0.12, revenue of $0.05M

Conference Call to be held Wednesday, March 23, 2022 at 5:00 pm (EST) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeu...

Conference Call to be Held on Wednesday, March 23, 2022 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunothe...

The FDA's rejection on Thursday of a citizen petition related to Cassava Sciences' (NASDAQ:SAVA) experimental Alzheimer's treatment simufilam has rekindled a long-time debate over how the petitions are being used by some, especially rival companies and those with deep pockets. The abilit...

Navidea Biopharmaceuticals (NYSE:NAVB) is trading ~20% higher on Monday after announcing that the company and the University of Pennsylvania entered into a sponsored research agreement to evaluate the potential of Tc99m tilmanocept imaging as a prognostic marker in glioblastoma. Acc...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the signing of a Sponsored Research Agreement with the Unive...

Navidea Biopharmaceuticals (NYSE:NAVB) announced on Thursday that it received a letter from the NYSE American stating that the company has failed to comply with the continued listing standards of the stock exchange. The company is required to submit a plan on regaining compliance by Feb. 27, ...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced settlement of the ongoing litigation with Platinum-Montaur L...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the launch of the NAV3-33 Phase 3 clinical trial titled ...

Navidea Biopharmaceuticals (NYSE:NAVB) announced the termination of a Stock Purchase Agreement executed by the company on Aug. 30, 2020. Per the terms of the deal, investors agreed to buy up to $25M worth of shares of the company’s common stock with a par value of $0.001 per share. The...